Wednesday 7 April

Thursday 8 April

Friday 9 April

Session 2: Pharmacogenetics

Invited lecture: Pharmacology and genetics of QTc prolongation

C. Funck-Brentano

Pres.

Intracellular pharmacokinetics of boosted and unboosted Atazanavir in HIV infected patients

M. Siccardi

Abs.

Pres.

Metabolism and excretion in humans of the pharmacoenhancer GS-9350

 A. Mathias

Abs.

Pres.

Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP)

A. D'Avolio

Abs.

Pres.

A novel application of population pharmacokinetic analysis: simulating nevirapine dose adjustment according to CYP2B6 516G>T polymorphism

 A. Schipani

Abs.

Pres.

Investigation of the association of CYP2B6 haplotypes with Efavirenz plasma conentrations in a Chilean HIV cohort

A.Owen

Abs.

Pres.

Invited lecture: Pharmacogenetic information in drug labels: Process, Evidence and Examples

S. Robertson

Pres.

Session 3: Drug Interactions (I)

Invited lecture: Pharmacology of Anti-Influenza drugs and potential for interaction with ARV's

E. Acosta

N.A.

The effect of Etravirine alone and with boosted protease inhibitors on the pharmacokinetics of the integrase inhibitor, S/GSK1349572

S. Piscitelli

Abs.

Pres.

Effect of Efavirenz and Darunavir/Ritonavir on bilirubin levels in healthy adult volunteers: Role of induction of UGT1A1 and bile efflux transporters

L. Lee

Abs.

Pres.

Relative bioavailability and pharmacokinetics of Darunavir when boosted with the pharmacoenhancer GS-9350 versus ritonavir

A. Mathias

Abs.

Pres.

Session 4: Pharmacokinetics and Pharmacodynamics of Drug Efficacy and Toxicity

Generic  lopinavir/ritonavir is bioequivalent to Aluvia, but neither result in adequate lopinavir exposure  at 50% dose reduction: HIVNAT 085

J. van der Lugt

Abs.

Pres.

Lack of adherence to treatment drives Maraviroc exposure-response in the MERIT study in treatment-naïve HIV-1 infected subjects

L. McFadyen

Abs.

Pres.

Pharmacokinetics of QD Maraviroc co-administered as part of a novel NRTI-sparing regimen with Atazanavir/ritonavir in HIV treatment-naïve patients

M. Vourvahis

Abs.

Pres.

Impact of age on renal function in patients receiving tenofovir 

L. Goeddel

Abs.

N.A.